Page 31 - Oncology Coder News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Oncology coder. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Oncology Coder Today - Breaking & Trending Today

Pembrolizumab enhances progression-free survival in patients with HER2-positive gastro-esophageal cancer

1. Progression-free survival was significantly greater among patients in the pembrolizumab group compared to placebo (10.0 vs. 8.1 months). 2. 1% of patients in each group experienced treatment-related mortality. Evidence Rating Level: 1 (Excellent) Study Rundown: Limited evidence exists on combined PD-1 and HER2 blockade with chemotherapy in HER2-positive gastro-esophageal cancer. This randomized controlled trial ....

Rating Level , Metastatic Cervical , Between Oct , Esophageal Cancer , Gastric Cancer , Gastroesophageal Adenocarcinoma , Gastroesophageal Cancer , Chronic Disease ,